Literature DB >> 23747162

Microbial keratitis after Boston type I keratoprosthesis implantation: incidence, organisms, risk factors, and outcomes.

Michelle J Kim1, Fei Yu, Anthony J Aldave.   

Abstract

PURPOSE: To identify the incidence of and risk factors for microbial keratitis after implantation of the Boston type I keratoprosthesis (Massachusetts Eye and Ear Infirmary, Boston, MA).
DESIGN: Retrospective, single-surgeon consecutive case series. PARTICIPANTS: A total of 105 patients (125 keratoprosthesis procedures in 110 eyes) who underwent Boston type I keratoprosthesis implantation at the Jules Stein Eye Institute between May 1, 2004, and April 1, 2012.
METHODS: Data regarding ocular history, relevant intraoperative data, postoperative management, and outcomes were collected for each procedure. Risk factor analyses were performed using the Fisher exact test, log-rank test, and hazard ratio (HR). MAIN OUTCOME MEASURES: Incidence of microbial keratitis, organisms responsible, risk factors, and outcomes.
RESULTS: During the period under review, 20 presumed infectious infiltrates were diagnosed in 15 eyes (13.6%) of 15 patients (14.3%), for a rate of 0.073 infections per eye-year. The rate of culture-positive bacterial keratitis was 0.022 infections per eye-year, and the rate of culture-positive fungal keratitis was 0.015 infections per eye-year. Topical vancomycin use, topical steroid use, and contact lens wear did not increase the incidence of infectious keratitis, but prolonged vancomycin use was associated with an increased risk for fungal keratitis and infectious keratitis overall. Persistent corneal epithelial defect formation also was associated with an increased incidence of fungal keratitis and infectious keratitis overall. There were no cases of endophthalmitis resulting from infectious keratitis.
CONCLUSIONS: Infectious keratitis develops in 13.6% of eyes after keratoprosthesis implantation, with a similar rate of culture-positive bacterial and fungal keratitis. The observed rate of microbial keratitis suggests the need for additional topical antimicrobial prophylaxis after keratoprosthesis implantation in eyes at higher risk, such as those with persistent corneal epithelial defect formation or prolonged vancomycin use.
Copyright © 2013 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23747162     DOI: 10.1016/j.ophtha.2013.05.001

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  11 in total

Review 1.  Fungal Infections After Boston Type 1 Keratoprosthesis Implantation: Literature Review and In Vitro Antifungal Activity of Hypochlorous Acid.

Authors:  Silvia Odorcic; Wolfgang Haas; Michael S Gilmore; Claes H Dohlman
Journal:  Cornea       Date:  2015-12       Impact factor: 2.651

2.  Boston keratoprosthesis type 1: outcomes of the first 38 cases performed at Moorfields Eye Hospital.

Authors:  Chameen Samarawickrama; Nicholas Strouthidis; Mark R Wilkins
Journal:  Eye (Lond)       Date:  2018-02-14       Impact factor: 3.775

3.  Artificial corneas versus donor corneas for repeat corneal transplants.

Authors:  Masako Chen; Sueko M Ng; Esen K Akpek; Sumayya Ahmad
Journal:  Cochrane Database Syst Rev       Date:  2020-05-13

Review 4.  Artificial corneas versus donor corneas for repeat corneal transplants.

Authors:  Esen K Akpek; Majed Alkharashi; Frank S Hwang; Sueko M Ng; Kristina Lindsley
Journal:  Cochrane Database Syst Rev       Date:  2014-11-05

Review 5.  The treatment of end-stage corneal disease: penetrating keratoplasty compared with Boston type 1 keratoprosthesis.

Authors:  Steven Bonneau; C Maya Tong; Yelin Yang; Mona Harissi-Dagher
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-04-06       Impact factor: 3.535

6.  Current Concepts in the Management of Unique Post-keratoplasty Infections.

Authors:  Julie M Schallhorn; Jennifer Rose-Nussbaumer
Journal:  Curr Ophthalmol Rep       Date:  2015-06-12

7.  COMPARISON OF VISUAL AND ANATOMICAL OUTCOMES OF EYES UNDERGOING TYPE I BOSTON KERATOPROSTHESIS WITH COMBINATION PARS PLANA VITRECTOMY WITH EYES WITHOUT COMBINATION VITRECTOMY.

Authors:  Jennifer I Lim; Lindsay Machen; Andrea Arteaga; Faris I Karas; Robert Hyde; Dingcai Cao; Marcia Niec; Thasarat S Vajaranant; M Soledad Cortina
Journal:  Retina       Date:  2018-09       Impact factor: 4.256

Review 8.  Keratoprostheses for corneal blindness: a review of contemporary devices.

Authors:  Venkata S Avadhanam; Helen E Smith; Christopher Liu
Journal:  Clin Ophthalmol       Date:  2015-04-16

9.  Prophylactic Vancomycin Drops Reduce the Severity of Early Bacterial Keratitis in Keratoprosthesis.

Authors:  Aris Konstantopoulos; Xiao Wei Tan; Gwendoline Tze Wei Goh; Padmanabhan Saraswathi; Liyan Chen; Chan Lwin Nyein; Lei Zhou; Roger Beuerman; Donald Tiang Hwee Tan; Jod S Mehta; Jod Mehta
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

10.  3D Functional Corneal Stromal Tissue Equivalent Based on Corneal Stromal Stem Cells and Multi-Layered Silk Film Architecture.

Authors:  Chiara E Ghezzi; Benedetto Marelli; Fiorenzo G Omenetto; James L Funderburgh; David L Kaplan
Journal:  PLoS One       Date:  2017-01-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.